Literature DB >> 12618332

Methylenetetrahydrofolate reductase polymorphism C677T is not associated to the risk of cervical dysplasia.

A F Lambropoulos1, T Agorastos, Z J Foka, S Chrisafi, T C Constantinidis, J Bontis, A Kotsis.   

Abstract

The aim of the study was to explore a possible association between methylenetetrahydrofolate reductase (MTHFR) C677T polymorphism and cervical neoplasia. A total of 229 women were subjected to cytologic and colposcopic evaluation. Ninety-one of them were found to be normal, and served as the control group, while the other 138 of them had present or past histologically proven cervical pathology (patients group). All patients and controls were investigated for the MTHFR C677T polymorphism. Statistical analysis between the groups of cases with cervical intraepithelial neoplasia or invasive cervical cancer and the control group did not reveal any statistically significant difference in the frequency of the MTHFR C677T polymorphism. Copyright 2002 Elsevier Science Ireland Ltd.

Entities:  

Mesh：

Substances：

Year:  2003        PMID： 12618332     DOI： 10.1016/s0304-3835(02)00675-4

Source DB:  PubMed          Journal:  Cancer Lett        ISSN： 0304-3835            Impact factor:   8.679


  16 in total

Review 1.  Cervical cancer with polymorphism in MTHFR C677T gene: a systematic review and meta-analysis.

Authors:  Xiao-Juan Xu; Li-Wei Zou; De-Bin Wang
Journal:  Mol Biol Rep       Date:  2012-10-16       Impact factor: 2.316

2.  MTHFR C677T and A1298C polymorphisms and cervical carcinoma susceptibility: meta-analyses based on 4,421 individuals.

Authors:  Wen-Lei Zhuo; Liang Zhang; Jun-Jun Ling; Yi Zhu; Zheng-Tang Chen
Journal:  Mol Biol Rep       Date:  2012-06-19       Impact factor: 2.316

3.  Methylenetetrahydrofolate reductase (MTHFR) and susceptibility for (pre)neoplastic cervical disease.

Authors:  Margreet Zoodsma; Ilja M Nolte; Martin Schipper; Elvira Oosterom; Gerrit van der Steege; Elisabeth G E de Vries; Gerard J te Meerman; Ate G J van der Zee
Journal:  Hum Genet       Date:  2005-01-06       Impact factor: 4.132

4.  Genotyping of the MTHFR gene polymorphism, C677T in patients with leukemia by melting curve analysis.

Authors:  Ugur Deligezer; Ebru Akisik; Nejat Dalay
Journal:  Mol Diagn       Date:  2003

5.  Methylenetetrahydrofolate reductase C677T polymorphism and susceptibility to cervical cancer and cervical intraepithelial neoplasia: a meta-analysis.

Authors:  Ya Li Luo; Ping Ye; Qiong Hua Zhang; Ting Ting Hu; Min Hong Luo; Mei Qing Li; Qing Chen
Journal:  PLoS One       Date:  2012-09-28       Impact factor: 3.240

6.  Methylenetetrahydrofolate reductase (MTHFR) polymorphisms and susceptibility for cervical lesions: a meta-analysis.

Authors:  Shuyu Long; Xingliang Yang; Xiaojiao Liu; Pei Yang
Journal:  PLoS One       Date:  2012-12-21       Impact factor: 3.240

7.  Association between Methylenetetrahydrofolate reductase C677T polymorphism and susceptibility to cervical cancer: a meta-analysis.

Authors:  Lili Yu; Kai Chang; Jian Han; Shaoli Deng; Ming Chen
Journal:  PLoS One       Date:  2013-02-19       Impact factor: 3.240

8.  A comprehensive review on host genetic susceptibility to human papillomavirus infection and progression to cervical cancer.

Authors:  Koushik Chattopadhyay
Journal:  Indian J Hum Genet       Date:  2011-09

9.  Thrombophilic Genetic Factors PAI-1, MTHFRC677T, V Leiden 506Q, and Prothrombin 20210A in Noncirrhotic Portal Vein Thrombosis and Budd-Chiari Syndrome in a Caucasian Population.

Authors:  Mario D'Amico; Pietro Sammarco; Linda Pasta
Journal:  Int J Vasc Med       Date:  2013-12-18

10.  Semantic integration of cervical cancer data repositories to facilitate multicenter association studies: the ASSIST approach.

Authors:  Theodoros Agorastos; Vassilis Koutkias; Manolis Falelakis; Irini Lekka; Themistoklis Mikos; Anastasios Delopoulos; Pericles A Mitkas; Antonios Tantsis; Steven Weyers; Pascal Coorevits; Andreas M Kaufmann; Roberto Kurzeja; Nicos Maglaveras
Journal:  Cancer Inform       Date:  2009-02-03
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.